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Interactions between cancer cells and the surrounding medium are not fully understood. In this study, we demonstrate that ascites
induces selective changes in the expression of integrins and urokinase plasminogen activator/urokinase plasminogen activator
receptor (uPA/uPAR) in ovarian cancer cells. We hypothesise that this change of integrin and uPA/uPAR expression triggers signalling
pathways responsible for modulating phenotype-dependent functional changes in ovarian cancer cells. Human ovarian surface
epithelial (HOSE) cell lines and epithelial ovarian cancer cell lines were treated with ascites for 48h. Ascites induced upregulation of
a6 integrin, without any change in the expression of av, b1 and b4 integrin subunits. Out of the four ovarian cancer cell lines studied,
ascites induced enhancement in the expression of uPA/uPAR in the more invasive OVCA 433 and HEY cell lines without any change
in the noninvasive OVHS1 and moderately invasive PEO.36 cell lines. On the other hand, no change in the expression of a6 integrin
or uPAR, in response to ascites, was observed in HOSE cells. In response to ascites, enhancement in proliferation and in adhesion was
observed in all four ovarian cancer cell lines studied. In contrast, no significant increase in proliferation or adhesion by ascites was
observed in HOSE cells. Ascites-induced expression of uPA/uPAR correlated with the increased invasiveness of HEY and OVCA 433
cell lines but was not seen in OVHS1, PEO.36 and HOSE cell lines. Upregulation of a6 integrin and uPA/uPAR correlated with the
activation of Ras and downstream Erk pathways. Ascites-induced activation of Ras and downstream Erk can be inhibited by using
inhibitory antibodies against a6 and b1 integrin and uPAR, consistent with the inhibition of proliferation, adhesion and invasive
functions of ovarian cancer cell lines. Based on these findings, we conclude that ascites can induce selective upregulation of integrin
and uPA/uPAR in ovarian cancer cells and these changes may modulate the functions of ovarian carcinomas.
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Cancer is a clonal phenomenon initiated by mutation in normal
cells that results in the generation of clones with diversified
phenotype (Greaves and Greaves, 2002). The growth of tumour
results in the dominance of proliferation of cancer cells compared
to normal cells. As the tumour grows, some cancer cells can
become genetically unstable and they may progressively acquire
aggressive properties that subsequently enable them to invade the
adjacent tissues, followed by systemic spreading, leading to fatal
outcome when left unchallenged (Greaves and Greaves, 2002).
Tumour microenvironment may have a differential effect on the
diversified clonal population of cancer cells enabling them to
respond to the environment in a phenotype-dependent manner
(Fidler, 2002).
Ascites is a common and distressing complication of ovarian
cancer (Hirabayashi and Graham, 1970). Ascites contains
growth factors and other extracellular matrix constituents
produced by tumour-infiltrating leucocytes and noncancerous
activated mesothelial cells (Offner et al, 1995). The shedding of
malignant cells from the surface of the ovarian tumour into
the peritoneal cavity is a common scenario in the progression of
ovarian carcinoma. Subsequent implantation of these shed tumour
cells to secondary sites along the mesothelial lining of the
peritoneum depends on their proliferation, adhesion, migration
and invasive phenotype. Ovarian cancer cells have the ability to
survive in the peritoneal tumour fluid or ascites as a single cell
or small clumps of aggregated cells or as spheroids. Hence, a
greater understanding of the biological changes induced by ascites
to the cancer cells is vital to understand the biology of ovarian
cancer progression.
Integrins are a family of heterodimeric trans-membrane
receptors that regulate cell–cell and cell–matrix interaction
(Hynes, 1992). In ovarian carcinoma, integrins have been shown
to mediate the organisation of extracellular matrix (ECM)
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s(Carreiras et al, 1999a), adhesion to ECM components (Lessan
et al, 1999) and cell motility (Carreiras et al, 1999b). The b1 family
of integrins and CD44 has been shown to mediate interactions
between ovarian carcinoma cells and the mesothelial cells that line
the abdominal organs (Lessan et al, 1999). CD44 binds the ECM
glycosaminoglycan hyaluronan with high affinity (Casey and
Skubitz, 2000) and affects cell adhesion (Lessan et al, 1999),
migration (Casey and Skubitz, 2000) and tumour growth (Strobel
et al, 1997) in ovarian carcinoma cells.
One critical pathway frequently implicated in cancer growth,
invasion and spread is the plasminogen (Plg) activation cascade
(Blasi, 1999). Activation of this cascade results in the formation of
cell-surface plasmin (Pn) that is essential for the degradation of the
ECM in surrounding tissue barrier (Blasi, 1999). In ovarian cancer,
a strong correlation has been reported between urokinase
plasminogen activator (uPA) antigen levels and poor prognosis
(Konecny et al, 2001) and uPA is localised in primary and
metastatic ovarian cancer specimens, as well as in the conditioned
medium of many (but not all) ovarian cancer cell lines (Ahmed
et al, 2002b). In addition, ovarian cancer patient’s tumour fluid
expresses a higher concentration of cell-free urokinase plasmino-
gen activator receptor (uPAR) (Pedersen et al, 1993) and high
levels of cell-associated uPA correlate with advance stage disease
(Tecimer et al, 2000).
One of the consequences of integrin ligation is activation of Ras
and its downstream Erk MAP kinase pathway that participates in
proliferative responses to multiple stimuli (Clark and Brugge,
1995). In addition, elevated uPAR expression in cancer cells is
maintained by constitutively activated Erk MAP kinase activity
(Lengyel et al, 1997), and recently it has been shown that blockade
of the Erk MAP kinase pathway suppresses growth of colonic and
ovarian tumours in vivo (Sebolt-Leopold et al, 1999). Collectively,
these data indicate that integrins in association with uPAR can
sustain activation of the Ras pathway to regulate proliferation and
proteolytic function of cancer cells.
The purpose of this study was to elucidate the biological role of
ascites in regulating integrin-mediated changes in ovarian cancer
growth and function. We examined selective changes in the
expression of integrins and uPA/uPAR in HOSE and ovarian
cancer cell lines in response to ascites. We show that a6b1
integrin and uPA/uPAR participate in ascites-mediated functional
changes of ovarian cancer cells. Our findings suggest that ascites
can induce markedly different functional outcomes in ovarian
carcinomas and that these differences can help one to under-
stand biological processes in vivo for better translation of
responses to treatment.
MATERIALS AND METHODS
Cell lines
The epithelial ovarian cancer cell lines HEY and PEO.36 were
obtained from Dr Georgia Chenevix-Trench, Queensland Institute
for Medical Research, Australia; the clear cell carcinoma cell line
OVHS 1 was from Dr Hideki Sakamoto, Nihon University School
of Medicine, Japan and epithelial ovarian cancer cell line OVCA
433 was from Dr Robert Bast, MD Anderson Centre, Houston,
USA. HOSE cells immortalised by transfection with SV-40 antigen
(Auersperg et al, 1999) were obtained from Professor Nelly
Auersperg, University of British Columbia, Vancouver, Canada.
HOSE cells were maintained in Medium 199/MCDB (1:1), while
ovarian cancer cell lines were maintained in RPMI 1640. Each
medium was supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 10mM HEPES, 100mgml
 1 of penicillin and
streptomycin. Cells were incubated at 371Ci n5 %C O 2 and
routinely checked for contamination. Viability was checked
routinely by Trypan blue exclusion method.
Antibodies and reagents
Monoclonal antibodies against a6 (ASC-6), av (AV1), b1(P5D2)
and b4(439-9B) integrin were obtained from Chemicon Interna-
tional (CA, USA). Monoclonal antibodies against uPA (394) and
uPAR (3936) were from American Diagnostica (Greenwich, USA),
anti-phospho-Erk from New England Biolab (MA, USA) and
tubulin was from Santa Cruz (CA, USA). Phycoerythrin-conjugated
goat anti-mouse IgG was obtained from Chemicon International
(CA, USA) and peroxidase-conjugated goat anti-mouse antibody
was from Bio-Rad (CA, USA).
The study was approved by the Research and Human Ethics
Committee (HEC#02/30 02/29) of Royal Women’s Hospital,
Melbourne, Australia. Ascites was obtained from patients diag-
nosed with Stage 2 or Stage 3 ovarian cancer, admitted to the
Oncology Dysplasia Unit of the Royal Women’s Hospital,
Melbourne. Two staff pathologists in the hospital performed the
pathology diagnosis of these patients. These patients were
diagnosed with serous cystadenocarcinoma and endometrioid
carcinoma. Protein content of ascites varied between 30 and
40mgml
 1.
Immunohistochemistry
Resected tissues not required for clinical analyses were obtained
from patients who presented for surgery at the Royal Women’s
Hospital, Melbourne, after the provision of a participant informa-
tion statement and only with informed consent. Normal ovaries,
needed for control comparisons, were removed from patients
undergoing surgery as a result of suspicious ultrasound images,
palpable abdominal masses and family history. Histological
grading of ovarian carcinoma was performed by the method
described by Silverberg (2000).
The tissue was frozen in embedding medium (OCT) by
immersion in isopentane cooled in dry ice. It was then stored
at  801C until needed. Frozen sections of the tissue were cut
at 5mm thickness and if not used immediately, stored at  201C.
For staining, sections were fixed in cold acetone for 15min and
held in Tris buffer (100mM, pH 7.6). Endogenous peroxidase
activity was removed using 3% hydrogen peroxide in methanol,
and endogenous biotin activity was blocked using diluted egg
white (5% in distilled water) and skim milk powder (5% in distilled
water) for 10min each. The sections were incubated for 1h in
primary antibody diluted 1:200 in 1% BSA in Tris buffer (100mM,
pH 7.6). Antibody binding was amplified using biotin and
streptavidin HRP (Chemicon, CA, USA) for 15min each and
the complex visualised using diaminobenzidine (DAB). Nuclei
were lightly stained with Mayer’s haematoxylin. An isotype
IgG1, suitably diluted, was substituted for the antibody as a
negative control.
Sections were assessed microscopically for positive DAB
staining. The extent of staining of integrin and uPAR expression
was scored in a blind fashion as 0 (o10%), 1 (11–25%), 2 (26–
50%), 3 (51–75%), 4 (76–90%) and 5 (490%) cells. Four sections
were assessed per tissue. In addition to the extent of staining,
tissue and cellular distribution of staining was determined.
Parallel frozen sections were stained with hematoxylin and
eosin to confirm the pathology diagnosis. Hematoxylin and
eosin and immunostained sections were reviewed indepen-
dently by two pathologists to verify cell type, grade and
immunohistochemical score.
Flow cytometric analyses
Monolayer cultures of HOSE and ovarian cancer cell lines in
serum-free medium were treated with ascites (3mgml
 1) or 10%
fetal calf serum (3mgml
 1) for 48h. Cells were washed twice with
PBS, harvested with trypsin-versene (CSL Biosciences, Australia)
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6 cells incubated with primary antibody for 30min at 41C
and washed twice with PBS. Cells were stained with secondary
antibody conjugated with phycoerythrin for 20min at 41C, washed
twice with phosphate-buffered saline (PBS) and then resuspended
in 0.5ml PBS prior to FACScan analysis (Becton Dickinson, NJ,
USA). All data were analysed using Cell Quest software (Becton-
Dickinson). Results are expressed as mean fluorescence units for
triplicate determinations.
Ras activation assay
Ras activation assay was performed as described in the
manufacturer’s instruction of the kit provided by Upstate
Biotechnology (NY, USA). Briefly, exponentially growing ovarian
cancer cell lines were serum starved for 16h, and then incubated in
serum-free medium7ascites (3mgml
 1) for 30min. Cells
were harvested, lysed in lysis buffer (125mM HEPES, pH 7.5,
150mM NaCl, 1% NP 40, 50mM MgCl2,5 m M EDTA and 10%
glycerol) and supernatant prepared by centrifugation for 20min at
41C at 900g. Ras activation assay was performed on cell lysates
containing equal amounts of protein. The assay method involves
immunoprecipitation of Ras-GTP and Ras-GDP from the
cell lysates treated with GTPgS and GDPgS. The immuno-
precipitates were detected by Western immunoblot using Ras
monoclonal antibody.
Immunoprecipitation and coimmunoprecipitation
analyses
Monolayer cultures of ovarian cancer cell lines were washed twice
with PBS and harvested with trypsin-versene. To detect cell surface
level of integrins, cells were lysed in lysis buffer (100mM Tris-HCl,
pH 7.5, 150mM NaCl, 1mM CaCl2, 1% Triton X-100, 0.1% SDS,
0.1% NP-40, 1mM vanadate, 1mgml
 1 pepstatin, 1mM PMSF,
5mgml
 1 Trasylol and 1mgml
 1 of leupeptin). Protein concentra-
tion of the cell lysates was determined and lysates containing equal
protein were used for immunoprecipitation. Cells lysates were
immunoprecipitated with mAbs against a6 (ASC-6), b1 (PD52), b4
(439-9B) integrins or isotype-matched control. Samples were
resolved in 7.5% SDS–PAGE gel under nonreducing conditions
and were transferred to nitrocellulose membranes. Membranes
were probed with the respective integrin antibodies followed by
peroxidase-labelled secondary antibody.
Western blotting
Exponentially growing HOSE and ovarian cancer cell lines were
serum starved for 16h. Cells were incubated in serum-free
medium7ascites (3mgml
 1) for 30min. Cells were harvested,
lysed in lysis buffer (125mM HEPES, pH 7.5, 150mM NaCl, 1% NP
40, 50mM MgCl2,5m M EDTA and 10% glycerol) and supernatant
prepared by centrifugation for 20min at 41C at 900g. Cell lysates
containing equal amounts of protein were electrophoresed on 10
or 18% SDS–PAGE gels under nonreducing or reducing condi-
tions and transferred to nitrocellulose membranes. Membranes
were probed with primary antibody followed by peroxidase-
labelled secondary antibody and visualised by the ECL (Amer-
sham, UK) detection system according to the manufacturer’s
instructions.
Cell proliferation assay
In total, 1 10
5 cells were plated in the presence and absence of
(3mgml
 1) FBS or ascites (3mgml
 1) in 24-well plates. After 24h,
0.5mCi of [
3H]thymidine was added to each well and cells were
incubated at 371C with 5% CO2 for an additional 16h. Cells were
washed with PBS, harvested and lysed in 1% Triton and measured
by liquid scintillation counting.
3D collagen cell proliferation assay
In order to assess if the proliferation of ovarian cancer cells in
response to ascites on monolayer cultures correlates with that in
3D cultures that mimics in vivo situation, proliferation assays were
performed by 3D collagen cell culture system (Chemicon Interna-
tional, CA, USA). Briefly, 1 10
4 cells were mixed with chilled
collagen solution and plated onto a 96-well plate (Nunc, USA). The
cells were incubated at 371C for 60min to initiate polymerisation
of the collagen. After the formation of the collagen gel, 200mlo f
growth medium was added to each well and cells were incubated at
371C with CO2 for 4 days with change of growth medium every day.
[
3H]thymidine (0.5mCi) was added to the wells for 16h. Cells were
removed from the collagen gels by digestion using Clostridium
histolyticum collagenase (100mgml
 1) for 30min at 371C. Cells
were collected by centrifugation, washed with PBS and dissolved in
1% Triton and measured by liquid scintillation counting.
Invasion assay
The invasive response of HOSE and ovarian cancer cells in
response to ascites was determined by using Matrigel-coated
invasion chambers (Becton and Dickinson, USA) as described
previously (Ahmed et al, 2003a). Cells were grown in the presence
or absence of ascites (3mgml
 1) for 24h. Approximately 2 10
5
cells were incubated in Matrigel-coated inserts in serum-free
medium. FBS (5%) was used as chemoattractant at 371C for 36h.
Matrigel inserts were removed and 0.5mCi of [
3H]thymidine was
added to the wells for 16h. Cells were washed with PBS, dissolved
in 1% Triton and measured by liquid scintillation counting.
Adhesion assay
HOSE and ovarian cancer cell lines were treated with ascites
(3mgml
 1) for 24h. In all, 1 10
5 cells were plated on 96-well
plates in triplicate at 371C for 90min. Cells were then washed three
times with PBS to remove nonadhering cells and the adherent cells
were fixed with 100% methanol for 5min at room temperature.
Cells were stained with 0.5% crystal violet for 15min. Stained cells
were washed with PBS, dried and absorbance was measured at
595nm with Vmax plate reader (Bio-Rad, CA, USA).
Statistical analysis
The association between the extent of a6 integrin immunohiosto-
chemical staining and histological grade of tumour was deter-
mined by w
2 analyses using the SPSS statistical package (Coakes,
1996). For uPAR immunohistochemistry, Student’s t-test was used
to test the association between the extent of staining and the
histological grade of the tumour. Student’s t-test was also used for
statistical analyses of proliferation, adhesion and invasion assays.
Statistical significance was indicated by Po0.05. Data are
presented as mean7s.e.m. Each experiment was repeated 3 times
and was carried out in triplicate.
RESULTS
a6, b1 and b4 integrin and uPA/uPAR profile of HOSE and
ovarian cancer cells in response to ascites
Ovarian cancer cell lines OVHS 1, PEO.36, OVCA 433 and HEY
have moderate to high expression of a6, av and b1 integrin
(Table 1). In contrast, OVHS 1, PEO.36 and HEY cell lines lacked
b4 integrin expression, while low expression of b4 integrin was
observed in OVCA 433 cell line (Table 1). The expression of av, b1
and b4 integrin (in OVCA 433 cell line only) remained unchanged
in response to ascites after 48h, while the expression of a6 integrin
was enhanced in OVHS 1, PEO.36, OVCA 433 and HEY cell lines
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was observed in HOSE cells (Figure 1, Table 1). In order to
determine if a6 integrin interacts with b1 integrin subunit and vise
versa, we immunoprecipitated a6 and b1 integrin from HEY and
OVCA 433 cell lines (Figure 2A, data shown for HEY). The
immunoprecipates were immunoblotted with anti-a6 and anti-b1
integrin antibodies, and protein bands with relative identical
mobility coimmunoprecipitating with a6 and b1 integrin were
identified (Figure 2A and B). Immunoblots of a6 integrin
immunoprecipitates also showed a band at 70–80kDa, a protein
previously identified as a6p, an incomplete form of a6 integrin
missing the extracellular domain associated with ligand binding
(Demetriou et al, 2004). a6p is not paired with b1 integrin subunit
(Figure 2A and B) as has been previously shown for other cancer
cells (Demetriou and Cress, 2004).
The expression of uPAR was enhanced in invasive OVCA 433
and HEY cell lines, while no such enhancement was observed in
noninvasive and moderately invasive OVHS 1 and PEO.36 ovarian
cancer cell lines and HOSE cells (Figure 1 and Table 1).
Enhancement of uPAR correlated with an increase in the cell
surface expression of uPA in OVCA 433 and HEY cells lines
(Table 1) while no change in uPA expression was observed in
HOSE, OVHS 1 and PEO.36 cell lines (Table 1). The change in the
expression of a6 integrin and uPA/uPAR was investigated in OVHS
1, PEO.36, OVCA 433 and HEY cell lines with five different samples
of ascites obtained from patients diagnosed with Stage 2 and Stage
3 ovarian cancer. These results indicate that soluble factors in
ascites can affect the expression of a6 integrin and uPA/uPAR in
ovarian cancer cells but not in HOSE cells.
Immunohistochemical localisation of a6 and b1 integrin
and uPAR in ovarian carcinomas
Immunohistochemical expression of a6 and b1 integrin and uPAR
was evaluated in normal ovaries, benign, grade 1, 2 and 3 tumours.
Of the eight benign tumours, six were of serous and two of
mucinous origin. All eight grade 1 tumours were of endometriod
subtype, while three of the grade 2 tumours were of serous origin
and the remaining two were of endometriod subtype. Of the 13
grade 3 tumours, 10 were of serous, one endometrioid and two
clear cell carcinoma subtype.
In the normal and benign ovarian tumours, the expression of a6
integrin was confined to the basal layer of epithelial cells which
displayed continuous labelling (Figure 3A). When blood vessels
were present on the section, staining of endothelial cells was also
observed. In a few cases, staining of the medullary stroma of the
normal ovaries was also evident. a6 integrin expression occurred
in a scattered heterogenous fashion in ovarian tumours
(Figure 3C). In all malignant tumours, the basal membrane
reactivity was present in a discontinuous fashion. Blood vessel
staining of endothelial cells was also evident in some tumour
sections. a6 integrin epithelial staining was significantly higher in
high-grade tumours compared to benign and grade 1 tumours and
normal ovaries (w
2¼27.41, df¼12, Po0.05) (Table 2a). In
contrast, the basement membrane a6 integrin expression was
lower in high-grade tumours (w
2¼16.85, df¼12, Po0.05) while
no significant differences in the blood vessel expression of a6
integrin was evident.
All normal and tumour specimens examined demonstrated
extensive staining of b1 integrin subunit (data not shown). The
expression of integrin was present in both epithelium and stroma
with little or no difference in distribution between the different
types or grades of tumour.
No expression of uPAR was evident in six normal ovaries
examined (Figure 3B and Table 2b). The expression of uPAR was
also absent in benign tumours. All ovarian malignant tumours
showed some degree of epithelial staining for uPAR (Table 2b).
Greater extent of staining was evident in advanced grade 3
Table 1 Expression of a6, av, b1 and b4 integrins and uPA and uPAR in
ovarian cancer and HOSE cells in response to ascites
Antigen
expression
(MIF) OVHS 1 PEO.36 OVCA 433 HEY HOSE 80
a6 integrin
 as 6776 10287112 20473 346750 88710
+as 176724 1343752 405750 542778 90712
av integrin
 as 90786 7 785 3 76 12078
+as 88710 72784 8 729 0 74N D
b1 integrin
 as 135711 281710 2308788 1298720
+as 17174 345714 2147728 1516780 ND
b4 integrin
 as 5701 0 702 0 705 70
+as 5701 0 701 8 705 70N D
uPA
 as 10705 701 2 702 8 741 0 70
+as 12704 702 6 72 100712 1270
UPAR
 as 12705 701 2 703 4 715 1070
+as 15706 702 4 717 0 728 870
MIF¼mean intensity of fluorescence; as¼ascites; ND¼not determined. The values
are 7s.e.m. of experiments repeated with three different ascites. uPA¼urokinase
plasminogen activator; uPAR¼urokinase plasminogen activator receptor.
Table 2b Expression of uPAR in 40 normal and ovarian tumour tissues
Histology
No. of
patients
Basement
membrane Epithelium Blood vessels
Normal 6 0 0 0
Benign 8 0 0 0
Grade 1 8 0 1 (5), 2 (3) 0
Grade 2 5 0 1 (2), 2 (3) 0
Grade 3 13 0 2 (5), 3 (4), 4
(4)
0
The extent of uPAR staining was scored as described for a6 integrin staining.
Student’s t-test was used to test the association between the extent of staining of
uPAR and the histological grade of tumour. Greater extent of staining was observed
in grade 3 tumours compared to grade 1/2 tumours (Po0.01).
Table 2a Expression of a6 integrin in 40 normal and ovarian tumour
tissues
Histology
No. of
patients Epithelium
Basement
membrane Blood vessels
Normal 6 0 (6) 4 (1), 5 (4) 4 (4), 5 (1)
Benign 8 0 (7), 3 (1) 4 (6), 5 (2) 3 (3), 4 (2), 5 (3)
Grade 1 8 0 (5), 2 (3) 4 (4), 5 (4) 3 (3), 3 (3), 5 (2)
Grade 2 5 0 (2), 2 (1), 3 (2) 3 (1), 4 (2), 5 (2) 2 (3), 3 (2)
Grade 3 13 2 (6), 3 (7), 4 (1) 2 (3), 3 (3), 4 (3),
5 (5)
2 (6), 3 (5), 4 (3)
The extent of a6 integrin expression was scored in a blind fashion as 0 (o10%), 1
(11–25%), 2 (26–50%), 3 (51–75%), 4 (76–90%) and 5 (490%). For each tissue,
four sections were studied and the whole tissue was analysed. The values in
parentheses indicate the number of tissues with the extent of staining indicated in the
respective columns. For each tissue, four sections were studied and the entire section
was analysed. Epithelial expression of a6 integrin was significantly higher in high-grade
tumours compared to benign and grade 1 tumours and normal ovaries (w
2¼27.41,
df¼12, Po0.05). In contrast, the basement membrane a6 integrin expression was
lower in high-grade tumours (w
2¼16.85, df¼12, Po0.05), while no significant
differences in the blood vessel expression of a6 integrin was evident.
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stumours compared to grade 1/2 tumours (Po0.01) (Figure 3D).
However, no staining of basement membrane and stroma was
evident using this antibody.
Proliferation of ovarian cancer cells in response to ascites
As ascites is a rich source of soluble growth factors, we determined
the proliferative response of HOSE and ovarian cancer cell lines in
response to ascites in monolayer cultures over 24h. The
noninvasive OVHS1 and moderately invasive PEO.36 cell lines
showed 2–2.5-fold increase in proliferation compared to 1.4–1.5-
fold increase in invasive HEY and OVCA 433 cell lines (Figure 4A,
Po0.01). No significant increase in proliferation was observed in
HOSE cells (Figure 4A). To determine if ascites-induced enhance-
ment in the proliferative response in monolayer cultures correlated
with that in 3D collagen gels, the assay was repeated with five
different ascites samples in 3D collagen gel system over 5 days. The
noninvasive OVHS 1 and moderately invasive PEO.36 cell lines
showed 1.5–2.2-fold (Po0.02) increase in the proliferative
response compared to only 1.1–1.3-fold (Po0.02) increase in
invasive OVCA 433 and HEY cell lines (Figure 4B). Inhibitory
antibodies against a6 and b1 integrin (5mgml
 1) inhibited both
ascites-induced and basal proliferation of noninvasive OVHS 1 and
invasive HEY cancer cell lines (Figure 4C, Po0.01). No effect on
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Figure 1 Flow cytometric analyses of (A, B) a6 integrin; (C, D) uPAR and (E, F) uPA in OVCA 433 and HOSE 80 cell lines in response to ascites
(3mgml
 1). The median intensity of fluorescence was measured (MIF, arbitrary units, log scale) and is shown in the inserts of each cell line. The filled
histogram in each figure is of control IgG, black lines indicate the expression of protein in the absence of ascites (C), while broken lines demonstrate protein
expression in the presence of ascites (as) after 48h. Results are representative of five experiments.
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that a6 and b1 integrin are involved in ascites-induced and normal
proliferation of ovarian cancer cells.
Adhesion of ovarian cancer cells in response to ascites
To determine if the soluble growth factors in ascites have any effect
on the adhesion of ovarian cancer cells, we investigated the
adhesive response of HOSE and ovarian cancer cell lines in
response to ascites. The four ovarian cancer cell lines used in the
study showed enhanced adhesion when stimulated by ascites for
24h (Figure 5). OVHS 1 and PEO.36 cells showed two-fold more
adhesion compared to 1.4–1.5-fold adhesion (Po0.01) observed
in OVCA 433 and HEY cell lines. Ascites-induced and basal
adhesive response of the ovarian cancer cell lines was suppressed
by inhibitory antibodies against a6 and b1 integrin (5mgml
 1) but
not by control IgG (Figure 5, Po0.01). Ascites had no effect on the
adhesion of HOSE cells under similar conditions (data not shown).
Invasion of ovarian cancer cells in response to ascites
Growth factors like epidermal growth factor (EGF), lysopho-
sphatidic acid (LPA) and hepatocyte growth factor (HGF) are
important constituents of ascites (Richardson et al, 2002)
(Sandmann et al, 2003). As these growth factors have been shown
to enhance the invasion of cancer cells (Ueoka et al, 2003), we
compared the invasive potential of the four ovarian cancer cell
lines stimulated for 24h with ascites using Matrigel Boyden
chambers. HOSE and OVHS1 cell lines showed no invasion
capacity through the chambers irrespective of the presence or
absence of ascites (Figure 6A). Even though PEO.36 cells were
moderately invasive, invasive capacity was not significantly
enhanced in response to ascites (Figure 6A). In contrast, OVCA
120 kDa
120 kDa
80 kDa
IPs IgG 6 1
IPs IgG 6 1
1
integrin
6
integrin
A
B
Figure 2 a6b1 interaction in HEY cells. Monolayer cultures of HEY
cancer cell line was washed twice with PBS and harvested with trypsin-
versene. Cells were lysed in lysis buffer (100mM Tris-HCl, pH 7.5, 150mM
NaCl, 1mM CaCl2, 1% Triton X-100, 0.1% SDS, 0.1% NP-40, 1mM
vanadate, 1mgml
 1 pepstatin, 1mM PMSF, 5mgml
 1 Trasylol and Imgml
 1
of leupeptin). Protein concentrations of the cell lysates were determined
and lysates containing equal protein were used for immunoprecipitation.
Cells lysates were immunoprecipitated with mAbs against against a6 (43B-
9B), b1 (PD52) or isotype matched control. Samples were resolved in 7.5%
SDS–PAGE gel under nonreducing conditions and transferred to
nitrocellulose membranes. Membranes were then probed with (A) anti-
a6 integrin; (B) anti-b1 integrin antibodies and the interaction of a6b1
integrin was evaluated with ECL.
Figure 3 Expression of a6 integrin and uPAR in normal ovaries and ovarian tumours. Cryostat sections of ovarian tissues were stained by the
immunoperoxidase method for the expression of a6 integrin and uPAR as discussed in the Materials and Methods section. (A) Normal ovary, arrow
showing continuous basal expression of a6 integrin in the epithelium; (B) normal ovary, showing no expression of uPAR; (C) grade 3 serous ovarian tumour,
arrows indicating irregular expression of a6 integrin in the basal epithelial and (D) grade 3 serous ovarian tumour, arrows indicating cytoplasmic epithelial
staining of uPAR.
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s433 and HEY cell lines showed 1.5–2-fold enhanced invasion
(Po0.01) in the presence of ascites. The invasiveness of OVCA 433
and HEY cell lines correlated with an increase in cell surface bound
uPA and uPAR (Table 1). Ascites-induced invasiveness of OVCA
433 and HEY cell lines was inhibited by inhibitory antibodies
against a6 and b1 integrin and uPAR (5mgml
 1) (Figure 6B,
Po0.01) but there was no change in basal invasive response.
Control IgG had no effect on the invasiveness of OVCA 433 and
HEY cell lines. These data suggest that ascites-induced enhance-
ment of a6 and b1 integrin and uPAR may have a role in enhancing
the invasiveness of ovarian cancer cells.
Ascites activates Ras and downstream Erk pathway
Activation of Ras and downstream Erk pathway is involved in
maintaining growth, adhesion and invasiveness of cancer cells
(Ueoka et al, 2003). In order to assess if ascites can activate Ras/
Erk pathway to regulate proliferative, adhesive and invasive
functions of ovarian cancer cells, we investigated the effect of
ascites on this pathway. Ascites enhanced the activation of Ras, as
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Figure 5 Effect of ascites on the adhesion of HOSE and ovarian cancer
cell lines. The adhesive response of ovarian cancer cells in response to
ascites was determined as described in Materials and Methods. Ovarian
cancer cell lines were treated for 24h with 7ascites (3mgml
 1), cells
were washed and adhesion of the cells was measured using 96-well plates.
The experiment was repeated three times in triplicate.
Figure 4 Effect of ascites on the proliferation of HOSE and ovarian
cancer cells. The proliferative response of HOSE and ovarian cancer cells
was determined on monolayer cultures and by 3D collagen gel system as
described in Materials and Methods. (A) HOSE and ovarian cancer cell
lines were grown as monolayers on 24-well plates and treated with
7ascites (3mgml
 1) and the uptake of [
3H]thymidine was measured over
16h as described in Materials and Methods. The experiment was
performed three times in triplicate. (B) Ovarian cancer cell lines grown
in 3D collagen gel system were treated with five different ascites samples
and their proliferation response was measured. The experiment was
performed three times in triplicate. (C) Effect of a6 and b1 integrin
inhibitory antibodies on the ascites-induced proliferation of OVHS1 and
HEY cell lines in 3D collagen gel system.
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sevidenced by the increased Ras-GTP levels in all four ovarian
cancer cell lines studied (data shown for Hey and OVHS1 cell lines)
(Figure 7A and D). Activation of Ras correlated with the activation
of downstream Erk, indicating that ascites may induce activation
of Erk through a Ras-dependent pathway (Figure 7B). In order to
assess if a6b1 integrin and uPAR affect ascites-induced activation
of Ras and downstream Erk, cells were treated for 30min with the
inhibitory antibodies (5mgml
 1) before being exposed to ascites
for 30min. Inhibition of a6 and b1 integrin and uPAR signalling
pathway blocked activation of Ras and downstream Erk in HEY
cell line (Figure 7A and B). Similar effects of anti-a6 and anti-b1
integrin were observed in OVHS 1 cell line (Figure 7D and E) but
no effect of anti-uPAR antibody was observed on ascites-induced
Ras and Erk activation in OVHS 1 cell line (Figure 7D and E).
These data suggest that a6b1 integrin and uPAR expression have a
defined role in sustaining ascites-induced activation of signalling
pathways.
DISCUSSION
The microenvironment created directly or indirectly by the
tumours has an effect on the functional outcome of cancer cells
within a tumour (Fidler, 2002). Ascites is a physiological
manifestation of ovarian carcinoma arising from the tumour and
also from the noncancer-bearing peritoneal surface of the ovary
(Hirabayashi and Graham, 1970). It has long been known that
factors that increase vascular permeability are present in ascites
and contribute to its development (Zebrowski et al, 1999). These
include angiogenic factors such as vascular endothelial growth
factor (VEGF), HGF, basic fibroblast growth factor (bFGF),
inteleukin-12, etc. and growth factors such as EGF, LPA,
transforming growth factors a and b (TGF a and b), etc. (Zeimet
et al, 1998). These soluble factors provide a unique microenviron-
ment for ovarian cancer cells either encapsulated in the tumour or
floating as a single-cell suspension or aggregates of cells in the
peritoneal cavity or attached to the mesothelial lining of the
peritoneum. Previous studies have concentrated in investigating
the functional changes of ovarian cancer cells in response to
individual growth factors present in ascites such as VEGF
(Yabushita et al, 2003) or LPA (Bian et al, 2004). Yet, nothing is
known about the effect of combination of all these ascites-
associated soluble factors on the cellular growth and function of
different population of ovarian cancer cells. In this study, we have
focused in identifying some of the molecules that are regulated by
ascites with a view to gain better understanding of the ascites-
induced molecular mechanisms that may contribute to the
progression and dissemination of ovarian carcinomas.
We demonstrate that the ovarian cancer cell lines undergo
selective increase in a6 integrin subunit expression in ovarian
cancer cells but not in HOSE cells. Ascites had no effect on the
expression of av and b1 integrins. No expression of b4 integrin was
observed in three of the four ovarian cancer cell lines studied,
while very low expression of b4 integrin was observed in OVCA
433 cells. b4 integrin expression in OVCA 433 cells remained
unchanged in response to ascites. a6 integrin but not the a6p
variant interacts with b1 integrin subunit in ovarian cancer cells.
The lack of expression of b4 integrin in ovarian cancer cells is
consistent with previous studies reporting deficiency of b4 integrin
expression in malignant cells derived from the ascites of the
ovarian cancer patients (Skubitz, 2002). As most ovarian cancer
cell lines are derived from the ascites of cancer patients, the lack of
b4 integrin subunit in these cell lines is not unexpected. These
observations are consistent with those reported for prostate cancer
as the progression of the cancer from intraepithelial neoplasia to
invasive prostate carcinoma results in loss of b4 integrin
expression and is replaced by alternative a6b1 integrin functions
(Demetriou and Cress, 2004). Increase in a6 integrin expression
has been reported previously for cells undergoing malignant
transformation such as fibroblasts (Lin et al, 1993), mouse
epidermal keratinocytes (Van Waes et al, 1995), hepatocytes
(Begum et al, 1995), Lewis lung carcinoma cells and osteocarci-
nomas (Gomez et al, 1992). As ascites is one of the contributing
factors in the dissemination of ovarian carcinoma, it would not be
unreasonable to expect enhanced expression of a6 integrin in
ovarian cancer cells in response to ascites.
Strong expression of a6 integrin was observed in the intact
basement membrane underlying the surface epithelial layer of
normal ovaries. In ovarian tumours, there was a loss of the regular
basement membrane resulting in irregular staining of a6 integrin.
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Figure 6 Effect of ascites on the invasion of HOSE and ovarian cancer
cell lines. The invasive potential of HOSE and ovarian cancer cells was
determined by Matrigel Boyden chamber as described in Materials and
Methods. (A) HOSE and ovarian cancer cell lines were treated with
7ascites (3mgml
 1) and their invasion capacity was measured in serum-
free medium using 5% FBS as chemoattractant. The experiment was
performed three times in triplicate. (B) Effect of a6, b1 integrin and uPAR
inhibitory antibodies on the ascites-induced invasion of OVCA 433 and
HEY cell lines.
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sIn ovarian carcinomas, staining for a6 integrin was confined to
irregular basal surfaces of the epithelial cells, where they were in
contact with the basement membrane. Epithelial staining of a6
integrin was significantly higher in high-grade tumours compared
to normal ovaries and benign tumours, while the staining of
basement membrane was reversed. These results are consistent
with expression of a6 integrin shown to correlate with the
expression of basement membrane laminin in serous ovarian
carcinoma (Skubitz et al, 1996). In another study, the expression of
a6 integrin was shown to correlate with the degree of ovarian
carcinoma tumour differentiation (Bottini et al, 1993). Our results,
however, did not show such a correlation. As a6 integrin
(combines with b1o rb4 integrin) is a major laminin receptor
for adhesion in laminin-rich basement membranes, one can
speculate that tumour-induced irregular patterns of basement
membrane distribution can result in the loss of regular adhesion of
cancer cells with subsequent exfoliation of cells into the
peritoneum. As exfoliated ovarian cancer cells in the peritoneum
require cell–cell or cell–ECM adhesion to grow and metastasise at
sites within the peritoneum, the induction of microenvironment-
induced expression of adhesion and metastasis-related molecules
may serve to regulate the process of ovarian cancer growth,
adhesion and invasion.
In this study, enhancement in the proliferation and adhesion of
ovarian cancer cell lines in response to ascites was observed.
However, these responses were significantly greater in noninvasive
and moderately invasive ovarian cancer cell lines compared to
invasive cell lines. Ascites, however, did not induce significant
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Figure 7 Effect of ascites on the activation of Ras and Erk pathway in HEY and OVHS 1 cell lines. Activation of Ras and downstream Erk was performed
as described in Materials and Methods. (A, D) HEY and OVHS 1 cells were serum starved for 16h and then treated with ascites in the presence or absence
of inhibitory antibodies for 30min. Cells were lysed and Ras-GTP and Ras-GDP were immunoprecipitated as described in Materials and Methods. Equal
amount of protein was loaded in each lane. Lanes 1, 3, 5, 7 and 9 demonstrate expression of Ras-GTP, while lanes 2, 4, 6, 8 and 10 demonstrate the
expression of Ras-GDP. (B, E) Effect of ascites and a6, b1 integrin and uPAR inhibitory antibodies on the ascites-induced activation of Erk in HEY and OVHS
1 cells. (C, F) b-Tubulin staining of the cell lysate to show protein loading.
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sincrease in the proliferation or adhesion of HOSE cells. Ascites also
enhanced the invasiveness of invasive ovarian cancer cell lines and
this enhancement in invasiveness correlated with the increment
of uPA/uPAR expression. However, no enhancement in the
invasiveness or increment in uPAR expression was observed in
HOSE cells. These data indicate that enhancement of a6 integrin
and uPA/uPAR in ovarian cancer cells occurs specifically in
the presence of ascites without affecting normal ovarian epithelial
cell function. Proinvasive properties of ovarian cancer ascites-
derived membrane vesicles have been reported recently (Graves
et al, 2004).
Recently, we have shown that ascites enhances the expression of
integrin-linked kinase and its downstream Akt pathway in ovarian
cancer cells but not in HOSE cells (Ahmed et al, 2003b). Moreover,
lysophosphatidic acid has been shown to stimulate ovarian cancer
cell migration via the Ras-MEK Kinase pathway (Bian et al, 2004).
In this study, we demonstrate that ascites-induced proliferation,
adhesion and invasion of ovarian cancer cells correlated
with activation of Ras and downstream Erk pathway. Inhibition
of a6o rb1 integrin or uPAR signalling pathway inhibited ascites-
induced activation of Ras and Erk pathway with subsequent
inhibition in proliferation, adhesion and invasion of ovarian
cancer cells. These observations suggest that a6b1 integrin
and uPAR play a significant role in ascites-regulated functions of
ovarian cancer cells.
Integrins directly associate with uPAR to mediate cellular
function (Wei et al, 1999). uPAR has been reported to associate
with many signalling molecules and to mediate signal transduction
(Aguirre Ghiso et al, 1999). Previously, we have shown loss of uPA/
uPAR-mediated Erk activation with downregulation of uPAR
expression in colon cancer cells (Ahmed et al, 2003a). uPA/uPAR
interaction with b1 integrin has been shown to activate Erk
pathway (Ahmed et al, 2003a) and disruption of this interaction
can result in loss of adhesion and tumour progression in nude
mice (van der Pluijm et al, 2001). The uPAR–integrin interaction
is crucial as many integrin receptors activate intracellular signal
pathways to fully activate cell survival and proliferation pathways
(Miyamoto et al, 1996). Recently, we have shown that the
cytoplasmic domain of avb6 integrin interacts with Erk and that
interaction is essential to maintain tumour growth in mice (Ahmed
et al, 2002a). b1 integrin function is regulated by uPAR and
downregulation of uPAR expression results in loss of uPAR/b1
integrin complex with subsequent inhibition of migration, matrix
degradation and invasion of colon cancer cells (Ahmed et al,
2003a). a6 integrin/uPAR interaction has been shown in breast and
prostate cancer cell lines (Demetriou and Cress, 2004), suggesting
that signalling through a6 integrin and uPAR may be essential for
ensuring cancer phenotype expression.
Primary tumours consist of subsets of cancer cells with different
dominant phenotypic characteristic (Mortarini and Anichini,
1993). In ovarian cancer, this scenario is more complicated as
the cancer is a compilation of different population of cells derived
from different clonal origins either attached to a substratum (ovary
or mesothelial layer) or floating in the peritoneum. In ovarian
cancer patients, normal ovarian cells are also exposed to ascites.
The fact that ascites has no effect on the proliferation and
invasiveness of HOSE cells suggest that normal epithelial ovarian
cellular function is not affected by ascites but rather ascites
regulates the dominant characteristic of the subset of ovarian
cancer cells. This scenario may provide functional advantage to
ovarian cancer cells contributing to the progression of cancer.
Hence, one can speculate that the presence of ascites will create a
microenvironment to help subsets of genetically programmed
ovarian cancer cells to perform their relevant functions through
enhanced expression of adhesive and metastasis-related proteins.
A more detailed understanding of the relative contribution of
ascites-regulated molecules on subsets of ovarian cancer cells will
promote better understanding of the biology of ovarian cancer and
will also result in improved treatment. The concept of ascites being
a cause rather then a manifestation of ovarian cancer progression
warrants further consideration.
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